{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-23-000142","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.745919+00:00","generated_at":"2026-06-12T05:48:32.865090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance","bullets":["Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).","Recurring revenue $3.6M, up 44% YoY; record consumable revenue; placed two new Growth Direct systems.","Cash, cash equivalents and investments $113.3M as of June 30, 2023; no debt; cash runway into 2026.","Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 system placements.","Appointed Kirk Malloy, Ph.D. as Chair of the Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-23-000142","json":"https://secwatch.observer/filing/0001380106-23-000142.json","markdown":"https://secwatch.observer/filing/0001380106-23-000142.md","text":"https://secwatch.observer/filing/0001380106-23-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/0001380106-23-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/rpid-20230804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:48:32.865090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1638eba875a76f949c3dbe77352d7e67a8613fb","claim":"RAPID MICRO BIOSYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue $5.0 million. Guidance reaffirmed.","evidence_excerpt":"expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/0001380106-23-000142-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$5.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}